key: cord-0685300-c3f2ik8i authors: Mohamed, Mahmoud; Nassar, Mahmoud; Nso, Nso; Alfishawy, Mostafa title: Massive gastrointestinal bleeding in a patient with COVID-19 date: 2021-05-14 journal: Arab J Gastroenterol DOI: 10.1016/j.ajg.2021.05.008 sha: b078c1d318897137f046f239d74ed92c0d129183 doc_id: 685300 cord_uid: c3f2ik8i Despite the emerging data about the thrombophilic effect of the novel Coronavirus [1] , the mutual relation of coagulation disorders and the COVID-19 pandemic is still not well understood. Various studies pointed to the significant role of the COVID-19 induced cytokine storm in development of the hypercoagulable state which leads to serious Thromboembolic Complications [2,3] . Nevertheless, some studies reported the development of Severe Immune Thrombocytopenia induced by the novel Coronavirus [4] . Other studies found a strong correlation between the COVID-19 disease and the development of disseminated intravascular coagulation ( DIC ) [5] . Patients with severe COVID-19 disease have an increased risk for development of gastrointestinal bleeding (GI) which may be related to stress [6] , critical illness or mechanical ventilation [7] . Nevertheless, some studies showed the ability of the novel Coronavirus to infect the epithelial cells of the GI tract [8] . Moreover, some data pointed to the ability of the novel Coronavirus even to infect the endothelium of the blood vessels [9] . The relation of the COVID-19 pandemic and the GI bleeding is understudied [10] . We present a case of GI bleeding in a patient with sever COVID-19 disease. We assume that COVID-19 disease can be a predominant factor for the development of DIC and GI bleeding. The prothrombotic outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV- 2) have already been extensively reported 1 . However, the pathophysiology that may help elucidate the clinical correlation between coagulation disorders and the coronavirus disease 2019 (COVID-19) remains unclear. According to several clinical studies, COVID-19-induced cytokine storm might trigger hypercoagulable states and thromboembolic events 2, 3 . The impact of COVID-19 on immune thrombocytopenia development is also emphasized 4 . In addition, a strong correlation is presumed to exist between COVID-19 and disseminated intravascular coagulation (DIC) 5 . Moreover, gastrointestinal (GI) bleeding in COVID-19 scenarios increases the risk of irreversible stress 6 , critical illness, or mechanical ventilation 7 . COVID-19 might invade the epithelial cells of the GI tract 8 . Several clinical data highlighted the ability of COVID-19 to infect the endothelial cells 9 . However, current clinical studies have not unraveled the mechanisms responsible for inducing GI bleeding in patients with COVID-19 10 . Here, we present a case of GI bleeding in a patient with severe COVID-19. Our findings will encourage the scientific community to validate the presumed clinical correlation between COVID-19 and DIC/GI bleeding. A 75-year-old African-American male patient arrived in the emergency room with fever, cough, and nausea, preceded by malaise for 2 weeks. He had a past medical history of insulin-dependent diabetes, hypertension, and dyslipidemia. He received treatment for his symptoms and was discharged with a follow-up prescription. After 3 days, he redeveloped shortness of breath, thereby readmitted for further treatment. Chest x-ray revealed interval worsening of bilateral, predominantly bibasilar, interstitial, and alveolar opacities. Acute respiratory distress syndrome occurred; thus, supplemental oxygen therapy, intubation, and medical management were provided. The reverse transcription-polymerase chain reaction (RT-PCR) test revealed that he was positive for COVID-19. The medical management relied on azithromycin combined with hydroxychloroquine. However, acute renal failure developed in a few days; thus, he received heparin-free continuous renal replacement therapy (CRRT). After 9 days, he was extubated. When his renal function markedly improved, he was transferred to the medicine floor. Within a week of receiving CRRT, the patient developed hematochezia and became hemodynamically unstable. In the intensive care unit (ICU), he was assessed and diagnosed with hemorrhagic shock requiring massive blood transfusion, intubation (for airway protection), and inotropic support. Contrast-enhanced abdominal and pelvic computed tomography (CT) revealed bibasilar airspace disease in scanned lung zones and a fat-containing ventral abdominal wall hernia with bowel loops. The diagnostic assessment excluded the possibility of incarceration and active GI bleeding. Thereafter, the patient underwent resuscitation in the ICU, followed by a repeat CT assessment, which ruled out the development of bleeding episodes. Unfortunately, the bleeding reoccurred; hence, an interventional radiologist initiated a pelvic (Figures 1 and 2) . The embolization procedure effectively controlled the bleeding episode. After 5 days, the patient was extubated, transferred back to the medicine floor, and later discharged to a skilled nursing facility. Our case report confirms that GI bleeding can adversely impact the course and outcomes of hospitalization in patients with COVID-19. COVID-19 is a predominant factor attributing to the development of DIC and GI bleeding. patients. GI symptoms ranging from nausea to severe GI bleeding were found in 79% of these patients. Real-time PCR from fecal samples was more effective in detecting SARS-CoV-2 than RT-PCR. The diagnostic assessment further revealed nucleocapsid protein and angiotensinconverting enzyme-2 in the GI epithelium of a patient with COVID-19 13 . Yang et al. (2020) reported GI bleeding in 4% of patients with COVID-19 in Wuhan Jinyintan Hospital. They further confirmed that GI bleeding is associated with a higher mortality risk and a worse adverse prognosis 8 . Thus, these findings further hint the impact of COVID-19 on the GI tract. The deleterious impact of COVID-19 on blood vessels may increase GI bleeding risk in patients with COVID-19. The recent reports about COVID-19 pathogenesis affirm hypercoagulability as a possible prognostic outcome of this disease [14] [15] [16] . Accordingly, many clinical studies emphasize on anticoagulant therapy to prevent and treat coagulopathy in COVID-19 scenarios 16, 17 . In another study, COVDI-19 had a deleterious impact on the structure and function of the vascular SARS-CoV-2 is a deleterious respiratory virus that discreetly disrupts the human body systems [18] [19] [20] [21] . Thus, prospective studies aim to determine the effect of COVID-19 on various organ systems. Deepening our knowledge on COVID-19 is the key to curb the progression of COVID-19 worldwide. In conclusion, our findings support the claim that SARS-CoV-2 infection can trigger episodes of DIC and GI bleeding. Future studies should investigate the potential of COVID-19 to disrupt the structure and function of the coagulation pathways, blood vessels, and epithelial cells in the GI tract. These assessments will help identify new and comprehensive prevention and treatment approaches to improve the mortality rate and prognostic outcomes of COVID-19. Clinical observation and management of COVID-19 patients Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: Report of the National Institute for Public Health of the Netherlands COVID-19 cytokine storm: The interplay between inflammation and coagulation Severe immune thrombocytopenia complicated by intracerebral haemorrhage associated with coronavirus infection: A case report and literature review COVID-19 and Coagulopathy: Frequently Asked Questions Stress ulceration: Prevalence, pathology and association with adverse outcomes Stress-induced ulcer bleeding in critically ill patients Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study COVID-19 lung problems may start in blood vessels Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission Hypercoagulability of COVID-19 patients in Intensive Care Unit: A report of thromboelastography findings and other parameters of hemostasis COVID-19-Related severe hypercoagulability in patients admitted to Intensive Care Unit for acute respiratory failure Thromboinflammation and the hypercoagulability of COVID-19 Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action Survival rate in acute kidney injury superimposed COVID-19 patients: A systematic review and meta-analysis COVID-19 and multi-organ response Comorbidities and multiorgan injuries in the treatment of COVID-19 COVID-19: Mitigation or suppression?